Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN 10 versus LIPOSYN III 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN 10 versus LIPOSYN III 10.
LIPOSYN 10% vs LIPOSYN III 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intravenous fat emulsion provides a source of calories and essential fatty acids as a component of parenteral nutrition. The lipid particles are metabolized similarly to endogenous chylomicrons, undergoing hydrolysis by lipoprotein lipase to release free fatty acids, which are then used for energy or stored.
Liposyn III 10% is an intravenous fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy production or stored. The emulsion particles are metabolized similarly to endogenous chylomicrons.
Intravenous infusion: 1-2 g/kg/day (10-20 mL/kg/day) as part of parenteral nutrition, not to exceed 2.5 g/kg/day. Infusion rate: initially 0.5-1 mL/min for 30 minutes, then increase to maximum 125 mL/hour if tolerated.
Intravenous infusion: 500 mL to 1000 mL per day, providing 10% lipid emulsion (100 g fat per liter), infused over 8-12 hours as part of parenteral nutrition, not to exceed 2.5 g fat/kg/day.
None Documented
None Documented
Lipid emulsion particles: elimination half-life of 10-15 minutes; triglycerides: terminal half-life of 1-3 hours, reflecting redistribution and clearance from adipose tissue; clinical context: half-life is dose-dependent and prolonged in hypertriglyceridemia, hepatic impairment, or sepsis.
Triglycerides in Liposyn III 10% have a terminal elimination half-life of approximately 0.5 to 1 hour in patients with normal lipid metabolism. In neonates or hepatic impairment, half-life may be prolonged.
Renal: negligible; biliary: negligible; fecal: negligible; eliminated via peripheral lipoprotein lipase-mediated hydrolysis and subsequent metabolism of fatty acids, with CO2 production (~50-60%) and recycling into triglycerides and phospholipids; complete clearance from plasma within 24 hours of infusion cessation.
Lipids are metabolized via hydrolysis by lipoprotein lipase into free fatty acids and glycerol. Free fatty acids undergo beta-oxidation or re-esterification. Elimination of CO2 via lungs; less than 5% excreted renally as glycerol and other metabolites.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion